For an 82-year-old male skilled‑nursing‑facility resident with coronary artery disease status post coronary artery bypass graft, heart‑failure with preserved ejection fraction due to ischemic cardiomyopathy, chronic kidney disease with recent acute kidney injury, recurrent falls, labile hypertension (systolic 170‑190 mm Hg, now 145/70 mm Hg) and intermittent bradycardia (heart rate low 50s, currently 58 bpm), how should the doses of metoprolol succinate, lisinopril, hydralazine, and torsemide be adjusted (increased, decreased, continued, or replaced)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medication Adjustment Recommendation

Increase hydralazine to 25 mg TID as the primary intervention for persistent systolic hypertension, while maintaining the current metoprolol hold parameters and continuing lisinopril and torsemide at current doses with close monitoring.

Rationale and Algorithmic Approach

Primary Action: Uptitrate Hydralazine

  • Hydralazine is the safest option to increase in this clinical scenario because it:

    • Does not worsen bradycardia (unlike beta-blockers)
    • Does not directly impair renal function (unlike ACE inhibitors at higher doses in AKI)
    • Provides effective afterload reduction for HFpEF 1
    • Has specific evidence in heart failure when combined with ACE inhibitors 2
  • The current dose of 10 mg TID is subtherapeutic; increase to 25 mg TID (standard dosing range is 25-100 mg TID)

  • Monitor for reflex tachycardia, though this is less concerning given baseline bradycardia tendency

  • The 2024 ESC guidelines support hydralazine as a second-line agent for resistant hypertension 3

Metoprolol Succinate: Maintain Current Strategy

  • Do NOT increase metoprolol given intermittent bradycardia (HR 50s, currently 58 bpm)
  • The hold parameter for HR <60 is appropriate and should be maintained 4
  • Current dose of 50 mg daily is reasonable for HFpEF, though note that evidence-based beta-blockers (metoprolol succinate, carvedilol, bisoprolol) have stronger data in HFrEF than HFpEF 1
  • Key caveat: In SNF residents with HFpEF, beta-blocker benefit is less established than in HFrEF, and bradycardia increases fall risk 1
  • Recent evidence suggests that modest bradycardia during GDMT is often a pharmacological effect rather than toxicity 5, but HR in the low 50s warrants caution in an 82-year-old with fall history

Lisinopril: Continue Current Dose with Vigilant Monitoring

  • Maintain lisinopril 10 mg daily - do not increase given recent AKI
  • The FDA label specifies dose reduction to 5 mg in CKD with creatinine clearance 10-30 mL/min 6
  • ACE inhibitors are foundational in HFpEF and post-CABG ischemic cardiomyopathy 1, 2
  • Critical monitoring: Check creatinine and potassium within 1-2 weeks after any medication changes
  • The combination of ACE inhibitor + diuretic increases risk of renal impairment 7, 6
  • Accept modest creatinine increases (up to 30% from baseline) if stable, as this often represents hemodynamic effect rather than nephrotoxicity 5

Torsemide: Continue Current Dose

  • Maintain torsemide 20 mg daily for volume management in HFpEF
  • This is appropriate for peripheral edema control 1
  • The FDA label warns that torsemide + ACE inhibitors increase hypotension and renal impairment risk 7
  • Monitor: Daily weights, volume status, and renal function
  • Adjust only if volume overload worsens or excessive diuresis occurs

Critical Monitoring Parameters

Within 1-2 weeks:

  • Blood pressure (target <140/90 mmHg, ideally <130/80 mmHg given CAD) 3
  • Heart rate (hold metoprolol if <60 bpm)
  • Creatinine and potassium (accept up to 30% creatinine increase if stable; hold lisinopril if K+ >5.5 mEq/L) 6, 5
  • Volume status and daily weights

Ongoing:

  • Fall risk assessment - bradycardia and hypotension are modifiable fall risk factors
  • Functional status and symptoms

Common Pitfalls to Avoid

  1. Do not reflexively stop ACE inhibitors for modest creatinine increases - up to 30% elevation is acceptable if stable and represents effective neurohormonal blockade 5

  2. Do not increase metoprolol to treat hypertension when bradycardia is present - this creates competing risks and increases fall danger

  3. Do not add additional nephrotoxic agents (NSAIDs, contrast) without careful consideration given CKD/recent AKI 7

  4. Do not interpret HR 50-60 as necessarily pathological during beta-blocker therapy unless symptomatic 5

Alternative Consideration

If hydralazine uptitration fails to control BP after 1-2 weeks, consider:

  • Adding amlodipine 2.5-5 mg daily (dihydropyridine CCB does not worsen bradycardia and is safe with beta-blockers) 3, 2
  • This combination (ACE inhibitor + beta-blocker + dihydropyridine CCB + diuretic) represents standard therapy for hypertension with CAD and HFpEF 3

The key principle in this 82-year-old SNF resident is prioritizing fall prevention and renal protection while achieving blood pressure control - hydralazine uptitration accomplishes all three objectives 1, 3.

Related Questions

What is the optimal strategy to improve blood pressure control in a 66-year-old patient with heart failure with preserved ejection fraction, severe chronic obstructive pulmonary disease, paroxysmal atrial fibrillation, and hypertension who is currently taking metoprolol succinate 25 mg, losartan 50 mg, and spironolactone 25 mg, with an average blood pressure of 140/80 mmHg?
What workup and treatment are indicated for a 70-year-old asymptomatic male establishing care who has severe hypertension (190/105 mmHg), HbA1c 6.7 %, and ECG showing left anterior descending artery disease, left atrial enlargement, and an old anteroseptal myocardial infarction?
Should a 74‑year‑old woman with hypertension, hypothyroidism, heart‑failure with preserved ejection fraction, paroxysmal atrial fibrillation, hyperlipidemia and a rapid rise in serum creatinine from 1.9 mg/dL to 2.75 mg/dL (estimated GFR decreasing from ~27 to ~17 mL/min) be taken to the emergency department?
In a 71-year-old woman with hypertension and coronary artery disease who has a dry, persistent cough and exercise‑induced chest tightness, with normal spirometry and normal chest radiograph, what is the best next step in management?
In a 50-year-old man with severe heart failure (ejection fraction 21%), NYHA class III, hypokalemia (serum potassium 3.0 mmol/L), on metoprolol and enalapril, which of the following statements is false: a) increase ACE‑inhibitor dose, b) prescribe an aldosterone antagonist, c) substitute potassium, d) prescribe an angiotensin‑II receptor blocker, e) evaluate for heart transplantation?
What is the appropriate evaluation and treatment for a patient with Sjögren’s syndrome who has a reduced diffusing capacity of the lungs (DLCO)?
Can minoxidil cause hypotension?
In a patient who had only light perception in one eye and then suddenly lost all vision (sudden blackout), does this suggest an acute ischemic event such as central retinal artery occlusion or anterior ischemic optic neuropathy?
Which apolipoprotein is considered the "bad" one that promotes atherosclerosis?
Can exposure to vapors, gases, dust, fumes (vapour‑gas‑dust‑fume), solvents, heavy metals, and gasoline cause hypertension, and what is the typical latency for its onset?
What is the appropriate initial management for a 35‑year‑old healthy male who experiences frequent palpitations after a 20‑hour travel day, has occasional premature atrial contractions (PAC) and premature ventricular contractions (PVC) on ECG/Holter, a normal echocardiogram, and no associated symptoms such as light‑headedness, chest pain, or shortness of breath?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.